TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · no major macro event
NBIX

Neurocrine Biosciences Inc

Healthcare · Drug Manufacturers - Specialty & Generic

138.40$ -0.4% vs. previous close Closing price · As of: Sep 25, 2026

Statements

Income Statement

Neurocrine Biosciences Inc (NBIX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 959 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement NBIX
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
499 515 515 590 622 628 573 688 795 806 815 959 3,374
11 8.5 7.5 9.2 8.0 9.3 9.2 11 14 18 14 23 69
488 507 508 581 614 618 563 676 781 788 801 936 3,305
142 138 159 191 195 186 263 244 250 258 296 327 1,131
204 219 243 242 234 288 277 286 292 302 319 440 1,352
346 356 409 436 430 476 540 531 542 577 615 783 2,516
141 150 99 145 184 142 24 146 239 211 186 153 789
1.1 1.1 1.1 50 – – – 0.0 – – – 2.9 –
116 198 35 99 190 163 15 160 292 239 247 162 940
33 51 -8.9 34 61 60 6.8 52 82 86 49 18 235
83 148 43 65 130 103 7.9 108 210 154 198 144 706
122 205 112 155 191 182 31 167 300 235 193 190 918

LTM = last twelve months (sum of the four most recent quarters).

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?